Aclaris Therapeutics Inc
Veridion Score
Composite trend over time
Why is ACRS moving today?
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ACRS.
ACRS insider activity
Aclaris Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for ACRS.
ACRS contract awards, year to date.
Public federal awards linked to this ticker.
ACRS lobbying filings, year to date.
Registered lobbying filings matched to Aclaris Therapeutics Inc.